Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.

@article{Watt2012ResponseTV,
  title={Response to valganciclovir in chronic fatigue syndrome patients with human herpesvirus 6 and Epstein-Barr virus IgG antibody titers.},
  author={Tessa Watt and Stephanie H. Oberfoell and Raymond Balise and Mitchell R. Lunn and Aroop K Kar and Lindsey E Merrihew and Munveer S Bhangoo and Jos{\'e} G. Montoya},
  journal={Journal of medical virology},
  year={2012},
  volume={84 12},
  pages={1967-74}
}
Valganciclovir has been reported to improve physical and cognitive symptoms in patients with chronic fatigue syndrome (CFS) with elevated human herpesvirus 6 (HHV-6) and Epstein-Barr virus (EBV) IgG antibody titers. This study investigated whether antibody titers against HHV-6 and EBV were associated with clinical response to valganciclovir in a subset of CFS patients. An uncontrolled, unblinded retrospective chart review was performed on 61 CFS patients treated with 900 mg valganciclovir daily… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 44 times over the past 90 days. VIEW TWEETS